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Abstract
Enterovirus 71 (EV-71) is the main causative agent of hand, foot and mouth disease (HFMD). In recent years, EV-71 infections
were reported to cause high fatalities and severe neurological complications in Asia. Currently, no effective antiviral or
vaccine is available to treat or prevent EV-71 infection. In this study, we have discovered a synthetic peptide which could be
developed as a potential antiviral for inhibition of EV-71. Ninety five synthetic peptides (15-mers) overlapping the entire EV-
71 capsid protein, VP1, were chemically synthesized and tested for antiviral properties against EV-71 in human
Rhabdomyosarcoma (RD) cells. One peptide, SP40, was found to significantly reduce cytopathic effects of all representative
EV-71 strains from genotypes A, B and C tested, with IC50 values ranging from 6–9.3 mM in RD cells. The in vitro inhibitory
effect of SP40 exhibited a dose dependent concentration corresponding to a decrease in infectious viral particles, total viral
RNA and the levels of VP1 protein. The antiviral activity of SP40 peptide was not restricted to a specific cell line as inhibition
of EV-71 was observed in RD, HeLa, HT-29 and Vero cells. Besides inhibition of EV-71, it also had antiviral activities against
CV-A16 and poliovirus type 1 in cell culture. Mechanism of action studies suggested that the SP40 peptide was not virucidal
but was able to block viral attachment to the RD cells. Substitutions of arginine and lysine residues with alanine in the SP40
peptide at positions R3A, R4A, K5A and R13A were found to significantly decrease antiviral activities, implying the
importance of positively charged amino acids for the antiviral activities. The data demonstrated the potential and feasibility
of SP40 as a broad spectrum antiviral agent against EV-71.
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Introduction
Enterovirus 71 (EV-71) belongs to the Human Enterovirus A
species of the genus Enterovirus within the family Picornaviridae [1].
EV-71 is composed of a single-stranded, positive-sense RNA of
approximately 7411 nucleotides enclosed within an icosahedral
capsid assembled from 60 copies of each of the four structural
proteins, VP1–VP4 [2].
EV-71 is one of the main etiological agents of hand, foot and
mouth disease (HFMD) which is generally regarded as a mild
childhood disease. HFMD is characterized by the development of
mild febrile illness with papulovesicular lesions on the hand, foot
and mouth. Several epidemics with high mortalities have occurred
in Europe in the 1970s (Bulgaria 1975 and Hungary in 1978) [3,4].
However, in recent years, it has emerged as a pathogen capable of
causing severe neurological complications such as brain stem
encephalitis and acute flaccid paralysis in infants and young
children (,6 years old) in Asia [5–7]. The impact of high fatalities
and long-term neurological sequelae in severely infected children
isolated from large scale HFMD outbreaks in Malaysia (1997),Tai-
wan (1998) and China (2009) indicated that EV-71 should be
regarded as the most feared neurotrophic enterovirus after the
eradication of poliovirus [8–10]. Currently, there is no vaccine for
prevention or antiviral to treat EV-71 infections [6,11]. Thus,
there is a need to develop better and effective antiviral agents to
treat future EV-71 infections.
Peptides that can block viral attachment or entry into host cells
have therapeutic potentials. Enfuvirtide is the first peptide-based
inhibitor of viral fusion approved by the FDA in March, 2003 for
clinical use. Enfuvirtide is a 36-amino acid peptide derived from
the HR2 sequence of the transmembrane protein gp41 of HIV-1
and is the prototype of new antivirals [12,13]. Recent studies have
discovered potential antiviral peptides against Hepatitis C by
screening 441 overlapping peptides (18-mers) covering the entire
HCV polyprotein [14] and a peptide derived from the pre-S1
surface protein of Hepatitis B virus was able to exhibit antiviral
properties against Hepatitis B virus infection [15]. Shih et al. (2004)
showed that BPROZ-194 binds to VP1 and was effective in
inhibiting viral attachment or viral uncoating. This indicated that
VP1 is a good target to derive potentially antiviral peptide
sequences [16].
In the present study, 95-overlapping peptides (15-mers) covering
the entire EV-71 capsid protein, VP1, were chemically synthe-
sized. These peptides were screened for their ability to inhibit EV-
71 infection in Rhabdomyosarcoma (RD) cells. Four peptides were
found to inhibit EV-71 infection by more than 80% when
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screened at 100 mM. One peptide, SP40, was selected for further
studies as it was able to inhibit EV-71 infection at 89% in RD cells




Rhabdomyosarcoma (RD, ATCC # CCL-136) cells, African
green monkey kidney (Vero, ATCC # CCL-81) cells, human
cervical adenocarcinoma Epithelial (HeLa, ATCC # CCL-2) cells
and human colon adenocarcinoma (HT-29, ATCC # HTB-38)
cells were obtained from American Type Culture Collection
(ATCC, USA). RD cells were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). Vero and HeLa cell lines were grown in Eagle
Minimal Essential Medium (EMEM) supplemented with 10%
FBS. HT-29 cells were grown in McCoy’s Medium supplemented
with 10% FBS. EV-71 strain 41 (5865/SIN/000009) (GenBank
accession number: AF316321), SHA66/97 (GenBank accession
number: AM396586); BrCr (GenBank accession number:
AB204852) and SHA52 (GenBank accession number:
AM396584) were propagated in RD cells supplemented with 2%
FBS. Coxsackievirus A16 (strain 22159) and poliovirus type 1 used
were clinical isolates and were propagated in RD and Vero cells
supplemented with 2% FBS, respectively.
Peptides
A set of 95 overlapping synthetic peptides spanning the entire
sequence of the VP1 capsid protein of Enterovirus 71 strain 41
(GenBank accession no. AF316321) was synthesized by Mimo-
topes Pty Ltd. (Clayton Victoria, Australia). Each peptide
contains 15-amino acid residues with 12 residues overlapping
with the adjacent peptides. All the peptides were reconstituted
in 100% dimethyl sulfoxide (DMSO) and stored at 280uC. The
peptide stock solution was diluted to the final concentration of
100 mM in the maintenance medium for initial screening. The
final concentration of the DMSO was less than 1%. The
peptide that showed inhibition of cytopathic effects was
identified and synthesized in larger amounts with .95% HPLC
purity grade.
In vitro EV-71 Inhibitory Assay of 95-overlapping
Synthetic Peptides
Approximately 1.56104 of RD cells were seeded into each well
of a 96-well plate and incubated overnight in a CO2 incubator
supplemented with 5% CO2. Prior to virus infection, EV-71
(100 PFU) were incubated with 100 mM of each synthetic peptide
for 1 hour at room temperature with gentle rocking and then
transferred to the plate containing RD cells. After adsorption for
1 hour, the inoculum was removed, and the cells were washed
twice with the serum free medium. An aliquot of 100 ml of the
fresh maintenance medium supplemented with 2% FBS was
added and the infected RD cells were incubated at 37uC for
24 hours. After 24-hour post infection, total infectious viral
particles were harvested and titrated with plaque assay.
EV-71 Plaque Assay
The plaque assay was carried out according to Sim et al. (2005)
with some modifications [17]. In brief, approximately 1.5X105
RD cells were seeded into each well of a 24-well plate, and
maintained in the complete growth medium. Prior to viral
infection, the complete growth medium was removed. After
adsorption for 1 hour, the inocula were removed, and the cells
were washed twice, overlaid with 500 ml plaque medium
(containing 1.2% carboxymethylcellulose and 2% FBS). After
48 hours of incubation, cells were fixed with 4% formaldehyde
and stained with 0.5% crystal violet.
Inhibition Concentration 50% (IC50) Determination
The IC50 values of SP40 against EV-71 strains, CV-A16 and
poliovirus type 1 were determined using comprehensive assay. In
brief, various concentrations of the peptide were prepared and
mixed with an equal volume of virus supernatant. The virus-
peptide mixtures were then used to infect peptide treated RD cells
at a MOI of 0.1. For EV-71, the viral titer was determined by the
plaque assay and total viral RNA was quantitated by the RT
TaqMan Real-time PCR assay. For CV-A16 and poliovirus type
1, the total infectious viral particles were harvested 24-hour post
infection and quantitated by TCID50 using Reed and Muench
method [18].
Reverse Transcription (RT) TaqMan Real-time PCR Assay
The primers and probewere designed according to Tan et al. [19].
The forward primer employed was 59-GAGCTCTATAGGAGA-
TAGTGTGAGTAGGG-39, the reverse primer was 59-AT-
GACTGCTCACCTGCGTGTT-39 and the TaqMan probe used
was 596-FAM-ACTTACCCA/ZEN/GGCCCTGCCAGCTCC-
lowa Black FQ-39. The viral RNA samples were extracted using
QIAamp Viral RNA mini kit (QIAGEN, Hilden, Germany)
according to the manufacturer’s instructions. The RT TaqMan
real-time PCR assay was performed with the OneStepTMPlus Real
TimeSystem (ABI,Carlsbad,USA)usingTaqManHFast virus1-step
master mix (ABI, Carlsbad, USA) with cDNA synthesis by reverse
transcription for 5 minutes at 50uC and subsequently amplified for
40 cycles at 95uC for 3 s, 60uC for 30 s.
SDS-PAGE and Western Blot Analysis
RD cells were seeded at 7.56105 cells/well in a 6-well plate and
followed by overnight incubation at 37uC in a CO2 incubator.
Prior to infection, both RD cells and virus were pre-treated with
various concentrations of the peptides for 1 hour. At 24-hour post-
infection, the cells and viruses were harvested. The cells were lysed
using 100 ml of ReadyPrep Sequential Extraction Kit Reagent 2
(Bio-Rad, USA). The protein concentration was determined using
the MicroBCA protein assay (Pierce, Rockford, USA). An aliquot
of 30 mg of each lysate was electrophoresed in a denaturing 12.5%
polyacrylamide gel. The proteins were transferred onto a PVDF
membrane (Millipore, Billerica, USA), and the membrane was
subsequently blocked in 5% skimmed milk powder in phosphate
buffered saline (PBS) with 0.05% Tween-20 for 1 hour in room
temperature. The membrane was incubated with 1:1000 diluted
anti-EV-71 monoclonal antibody (Millipore, Billerica, USA) or
1:1000 diluted b-actin antibody (Sigma, St. Louis, USA) for
1 hour at room temperature. After the membrane was washed, it
was incubated with 1:1000 diluted secondary antibody (HRP-
conjugated rabbit anti-mouse antibody, Sigma, St. Louis, USA) for
1 hour at room temperature. The immunoblots were developed
with the DAB substrate in stable peroxide substrate solution
(Pierce, Rockford, USA).
Mechanism of Action of SP40
RD cells were seeded at 1.56104 cells per well in a 96-well plate
and incubated overnight at 37uC in a CO2 incubator before EV-
71 infection with a MOI of 0.1 per well. Peptides were added at
various concentrations under the following conditions: (i) Cell
protection assay: RD cells were treated with various concentra-
Antiviral Peptide against EV-71 Infections
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tions of peptide (50 ml/well). After 1 hour, the cells were washed
twice with serum free medium and infected with 100 ml/well of
EV-71 (1.56104 PFU/ml) for 1 hour. The medium containing
virus was replaced with fresh maintenance medium and the viral
titer was determined 24-hour post-infection using plaque assay. (ii)
Post-infection assay: RD cells were first infected with EV-71 for
1 hour before addition of the peptide. The inocula were replaced
with fresh maintenance medium containing various concentrations
of peptide (50 ml/well) and the viral titer was determined 24 hours
later. (iii) Virucidal assay: EV-71 (16106 PFU/ml) was treated
with various concentrations of peptide in 100 ml of maintenance
medium for 1 hour. The treated virus was then diluted 200-fold
and used to infect cells for 1 hour. The diluted virus-peptide
mixtures were replaced with fresh maintenance medium, and the
plaque forming unit was determined 24 hours later. (iv) Viral
attachment assay: RD cells in the chamber slide (Lab-tek,
Rochester, USA) or a 96-well plate or a CellCarrier-96 optic
black plate (Perkin-Elmer, Waltham, USA) were pre-treated with
the peptide for 1 hour at 4uC and subsequently infected with EV-
71 at the MOI of 100 for 1 hour at 4uC. The infected cells in the
96-well plate were washed twice to remove unbound viral
particles, the attached EV-71 viral RNA were extracted and
quantitated by the RT TaqMan Real-time PCR assay. The
infected cells in the chamber slide and the CellCarrier-96 optic
black plate were fixed with 4% paraformaldehyde and permea-
bilized with 0.25% Triton-X. The slide was first blocked with
Image-iTTM FX Signal Enhancer (Invitrogen, San Diego, USA)
for 1 hour. Subsequently, anti-Enterovirus 71 monoclonal anti-
body (Millipore, Billerica, USA) was added into the cell-coated
well followed by 1:200 diluted Alexa Fluor 488 anti-mouse IgG
(Invitrogen, USA) as a secondary antibody. The nuclei of the RD
cells were stained with 4,6-diamidino-2-phenylindole (DAPI). The
slide was observed under Nikon Eclipse TE2000-E Fluorescence
Microscope and the CellCarrier-96 optic black plate was analyzed
by Cellomics High Content Screening ArrayScan VTI (Thermo
Fisher Scientific, USA) using Spot Detector Bio-Application. The
number of spots per field was determined.
Cytotoxicity Assay
Peptide cytotoxicity was determined by a commercially
available assay (Celltiter 96 AQueous One Solution Cell
Proliferation Assay Reagent, Promega, Madison, WI) following
the manufacturer’s instructions. Briefly, RD cells (1.5X104 cells/
well) were seeded in a 96-well plate, and the plate was incubated
for 24 hours at 37uC. An aliquot of 20 ml of the medium
containing the desired concentration of the SP40 peptide was
added to the cells. The final concentration of DMSO for all
peptide dilutions was adjusted to 0.6% to eliminate the effect of
DMSO variation on cell cytotoxicity. After incubation of the cells
in the presence of the SP40 peptide overnight at 37uC, 20 ml of the
96 AQqueous One Solution cell proliferation assay reagent were
added to each well. The plate was then incubated for 2 hours at
37uC and the absorbance at 490 nm was determined with a 96-
well plate reader.
Sequence Alignment and Structure Homology Prediction
The genome sequences of the EV-71 strain 41 (GenBank
accession number: AAK13008) and the Mahoney poliovirus strain
(GenBank accession number:1PO2_1) were searched using the
NCBI Protein website (http://www.ncbi.nlm.nih.gov/protein/).
The sequence of the EV-71, VP1 protein was aligned using Clustal
W2 program (http://www.ebi.ac.uk/Tools/Clustalw2/index.
html). The three-dimensional structure of the VP1-VP4 protein
complex of Mahoney strain poliovirus (PDB ID: 1HXS) was
selected to predict the possible position of SP40 by homology
modeling.
Results
Screening of the VP1 Capsid Protein Peptide Library
To test the potential of using peptides as an antiviral agent, a
library of 15-mer peptides (purity at 60–65%) corresponding to
residues 1 to 297 of the VP1 capsid protein and overlapping with
each other by 12 residues (6 residues on the C-terminal and N-
terminal, respectively) were synthesized. All the 95-overlapping
peptides were evaluated for their ability to reduce cytopathic
effects caused by EV-71 in RD cells, followed by plaque reduction
assay as described in the materials and methods. The criterion for
designating a peptide as antiviral is the inhibition of at least 80% of
plaque formation at a concentration of 100 mM. Fig. 1 shows the
locations of the peptides in the EV-71 genome and their antiviral
activities in the initial screen. Of the 95-overlapping peptides in
the library, there were four peptides, designated as SP40, SP45,
SP81 and SP82 that were found to exhibit inhibitory effects
against EV-71 plaque formation at 89.3%, 83.7%, 83.7%, and
82.5%, respectively (Fig. 1). The SP40 peptide was selected for
further analysis as SP40 showed the highest inhibition of both
cytopathic effect and plaque reduction. The amino acid sequence
of the SP40 peptide was highly conserved across all genotypes of
EV-71 (Table S1). SP40 is a 15-mer peptide (Ac-QMRRKVELF-
TYMRFD-NH2) spanning from position 118 to 132 in the VP1
capsid region. A scrambled-SP40 peptide, designated as SP40X
(Ac-REFTMKRMVLFRQDY-NH2), was synthesized and used as
a control throughout the experiments.
Synergistic Antiviral Activities of the SP40 Peptide
with SP81
To investigate whether the SP40 peptide exhibited synergistic
antiviral activities with other peptides, the SP40 peptide was mixed
with SP45, SP55 and SP81 (,70% purities) to a final
concentration of 200 mM. Our results demonstrated that the
SP40 peptide could best exhibit synergistic antiviral activities with
the SP81 peptide to achieve a total viral RNA inhibition of 99.7%
when compared to 92.0% being exhibited by 200 mM of the SP40
peptide alone. However, the SP40 peptide had less synergistic
effect when combined with the SP45 peptide or the SP55 peptide,
with viral RNA inhibitions of 94.3% and 96.0%, respectively.
When all the 4 peptides were combined, viral RNA inhibition
achieved was at 98.8%.
Antiviral Properties of SP40
To further confirm that the SP40 peptide inhibited EV-71
infection in RD cells, the peptide was synthesized on a larger scale
with .95% purity. The peptide was tested in the comprehensive
assay against EV-71 at a MOI of 0.1. The results confirmed that
SP40 inhibited viral plaque formation and RNA synthesis with
inhibition levels achieved at 96.3%60.8 and 92.0%69.3,
respectively when the peptide was applied at 200 mM (Fig. 2B,
Fig.3A and 3B). The SP40 peptide also significantly reduced viral
cytopathic effect and protein synthesis when tested in RD cells
(Fig. 2A, Fig. 2C). To determine whether the amino acid sequence
of the SP40 peptide is critical for the antiviral activities, the
antiviral property of the scrambled SP40X peptide was evaluated.
The data indicated that the SP40X peptide showed no significant
inhibition of EV-71 infection at 200 mM. Two independent
experiments confirmed that the SP40 peptide inhibited EV-71
strain 41 infection with an IC50 of 7.9 mM63.5 (Table 1).
Interestingly, the SP40 peptide also inhibited all three genotypes of
Antiviral Peptide against EV-71 Infections
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EV-71 (genotypes A, B and C) with IC50 values ranging from 6–
9.3 mM (Table 1, Fig. 3C). The SP40 peptide was found to inhibit
EV-71 induced cytopathic effects and viral RNA synthesis in Vero,
HeLa and HT-29 cell lines in a dose-dependent manner (Fig. 4A
and 4B). The SP40 peptide also exhibited antiviral activities
against CV-A16 and poliovirus type 1 with IC50 values of
6 mM60.8 and 18.22 mM610.4, respectively. However, the IC50
value against poliovirus type 1 was observed at a higher value
(Table 1). Hence, we concluded that the SP40 peptide exhibited a
broad-spectrum antiviral activity against all EV-71 genotypes as
well as other enteroviruses in various cell lines.
Mechanism of Action of SP40
We have found that the SP40 peptide exhibited the strongest
inhibitory effect when tested in the comprehensive assay with an
IC50 of 7.9 mM where both RD cells and EV-71 viral particles
were first pre-treated with the SP40 peptide separately before
infection (Fig. 3D). This suggested that the SP40 peptide could
exert its inhibition at the viral binding step in EV-71 infection or it
was virucidal to EV-71 viral particles.
To determine if the SP40 peptide could inactivate EV-71 viral
particles, viral supernatant at a MOI of 10 was incubated with the
SP40 peptide for 1 hour at room temperature, and subsequently
diluted 200-folds and viable viral particles were quantitated by the
plaque assay. The results demonstrated that the SP40 peptide
could not inactivate EV-71 even when the peptide tested was
present at a concentration as high as 200 mM. Hence, SP40
peptide was not virucidal to EV-71 viral particles (Fig. 3D).
To elucidate whether the SP40 peptide could inhibit the viral
binding step in EV-71 infection, RD cells were pre-incubated with
the SP40 peptide for 1 hour at room temperature before EV-71
infection. The IC50 value observed was 15 mM (Fig. 3D). The data
indicated that the SP40 peptide could disrupt or interfere the
binding of the EV-71 viral particles to cells or it could interfere
with post-binding steps. To address this, RD cells were pre-treated
with various concentrations of the SP40 peptide at 4uC for 1 hour,
followed by EV-71 inoculation at a MOI of 100 at 4uC. The EV-
71 viral particles that were attached to the RD cell surface were
determined by immunofluorescence assay as described in the
Materials and Methods. As shown in Fig. 5A, the number of EV-
71 viral particles (green fluorescence) attached to the RD cell
Figure 1. Identification of antiviral peptides. A library consisting of 95-overlapping peptides (15 mers) covering the entire EV-71 capsid protein,
VP1 was synthesized. Each peptide was screened at a presumptive concentration of 100 mM for its ability to inhibit EV-71 infection in plaque
reduction assay. The top line showed a schematic representation of the EV71 genome, and the activities of the peptides were shown at the bottom.
Arrows denote the four peptides that were positive in the assay.
doi:10.1371/journal.pone.0034589.g001
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surface was observed to be reduced when tested in the presence of
the SP40 peptide. The results from the Cellomics HCS ArrayScan
Spot Detector BioApplication assay showed that the number of
viral particles that were attached to the cell surface were reduced
from 210639 viral spots per field to 68620 viral spots per field in
a dose dependent manner (Fig. 5B). Total viral RNA determined
by real-time RT-PCR assay confirmed significant reduction of
viral RNA following treatment with the SP40 peptide before
infection with EV-71 at 4uC (Fig. 5C). To investigate if SP40
inhibited a post-binding step in EV-71 entry to the cells, RD cells
were incubated with EV-71 for 1 hour at 4uC, followed by the
addition of SP40. The cells were washed and immediately shifted
to 37uC for 1 hour to allow post-binding event. No inhibition of
plaque formation was observed (data not shown). The results
demonstrated that the SP40 peptide disrupted the binding of the
EV-71 viral particles to RD cells rather than at the EV-71 during
post-binding stage.
Figure 2. Inhibitory effects of SP40 and SP40X peptides in cytopathic effect, plaque formation and protein synthesis. (A) For
cytopathic effect, EV-71 at a MOI of 0.1 was pre-incubated with peptides for 1 hour before infection of peptide-treated RD cells. The images were
taken at 24-hour post-infection. (B) For plaque reduction assay, approximately 100 PFU of EV-71 were pre-incubated with peptides for 1 hour before
infection of peptide-treated RD cells. The cells were fixed with 4% formaldehyde and stained with 0.5% crystal violet at 48-hour post-infection. (C)
Western blot analysis of total protein isolated from virus-infected cells using the EV-71 monoclonal antibody (Millipore, Billerica, USA) and monoclonal
anti b-actin antibody (Sigma, St. Louis, USA).
doi:10.1371/journal.pone.0034589.g002
Table 1. IC50 of the SP40 peptide against various
enteroviruses.
EV-71 strains Genotypes Clinical manifestations IC50 (mM)
b
BrCr A Aseptic meningitis 9.362.5
SHA66/97 B3 HFMDa 660.7
41 B4 Fatal 7.963.5
SHA52 C2 HFMD 8.562.8
Coxsackievirus A16 – HFMD 660.8
Poliovirus type 1 – – 18.22610.4
aHFMD denotes hand, foot and mouth disease.
bThe IC50s are the mean 6 standard deviations determined from at least two
independent experiments.
doi:10.1371/journal.pone.0034589.t001
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The SP40 peptide was found to be non-inhibitory when added
one hour after RD cells were infected with EV-71. The IC50 of
SP40 peptide after 1 hour post-infection was established to be
200 mM (Fig. 3D).
Residues Critical for Antiviral Activity of SP40
To identify the residues in the SP40 peptide that are critical for
antiviral activity, 13 peptides with alanine substitution in each of
the amino acid position in the 15-mer SP40 peptide were
synthesized. The inhibitory effects in RD cells at 200 mM of all
peptides were evaluated. Reduction of viral RNA levels by each of
the peptides being evaluated was summarized in Fig. 6. Substi-
tution of the arginine residue at position 3 (P3) with alanine in the
SP40 peptide was found to significantly decrease the inhibitory
activity (from 95.9% to 61.8%) when compared to substitution at
other positions. When positively charged arginine or lysine
residues at positions 4, 5 and 13 (P4, P5 and P11) of the SP40
peptide were substituted with alanine, there were moderate losses
of activities (from 95.9% reduced to 74.3%, 70.9% and 70.6%,
respectively). With only one exception, substitution of the polar
methionine residue at position 12 with alanine in the SP40 peptide
also reduced the antiviral activity moderately to 74.7%. Alanine
substitutions of amino acids at other positions of the SP40 peptide
did not alter the antiviral activities when compared to the SP40
peptide. Our data indicated that the positively charged amino
acids were critical for the antiviral activities of the SP40 peptide.
Cytotoxicity Assay
To evaluate whether the SP40 peptide was cytotoxic to cells,
RD cells were treated with increasing concentrations of the SP40
peptide from 0 mM to 280 mM, and cell viability was determined
using CellTiter 96 AQueous One Solution Cell Proliferation Assay
Reagent (Promega, Madison, WI). We found that the SP40
peptide was non-cytotoxic to RD cells when tested at the
concentration of up to 280 mM. The SP40 peptide was also
non-cytotoxic to HeLa, Vero, HT-29 cell lines (data not shown).
Homology Modeling of EV-71
The EV-71 VP1 amino acid sequence was aligned with
Mahoney poliovirus using Cluster W2 program and the three
dimensional structure of the EV-71 capsid protein based on the
poliovirus model was analyzed by the NCBI Cn3D 4.3 software
(Fig. 7). The amino acid sequence of the SP40 in the 3D structure
is indicated in yellow. The 3D-homology structure of EV-71
indicated that part of the SP40 peptide was exposed on the
surface.
Discussion
A Pepscan strategy was employed to screen 95-overlapping
synthetic peptides corresponding to the VP1 capsid protein for
antiviral activity against EV-71. Four peptides SP40, SP45, SP81
and SP82 were found to exhibit significant antiviral activities. The
SP40 peptide was selected for further investigation as the amino
Figure 3. Antiviral activities of the SP40 and SP40X peptides.
Both RD cells and EV-71 were separately pre-incubated with increasing
concentrations of each peptide for 1 hour before viral inoculation. The
inhibitory levels of the peptides were evaluated at 24-hour post-
infection by (A) plaque assay and (B) RT TaqMan real-time PCR. (C)
Antiviral properties of the SP40 peptide against different EV-71 strains
in the comprehensive assay and (D) Mechanism of action studies: The
SP40 peptide was added to EV-71 infection at different time points
relative to viral inoculation as previously described in the Materials and
Methods.
doi:10.1371/journal.pone.0034589.g003
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acid sequence of SP40 is highly conserved across all EV-71
genotypes and sub-genotypes. Our results demonstrated that the
SP40 peptide inhibited EV-71 infection in a dose-dependent
manner corresponding to the reduction of viral RNA, VP1 protein
and plaque formation. The IC50 values reported in our studies
ranged from 6–9.3 mM against all representative strains of EV-71
genotypes A, B and C. Interestingly, the SP40 peptide also
inhibited CV-A16 and poliovirus type 1 infection in vitro, implying
that the SP40 peptide could function as a broad-spectrum antiviral
agent. However, a higher concentration of SP40 peptide was
required to block poliovirus type 1 infection. This could be due to
the high degree of dissimilarity of the amino acid sequence present
in EV-71 and poliovirus.
The possible mechanism of action of the SP40 peptide could be
either through direct viral inactivation or it could block viral
attachment and entry. Our data confirmed that the SP40 peptide
was not virucidal, but it blocked viral attachment to the cell-
surface and hence prevented EV-71 infection. Our immunofluo-
rescence assay and Cellomics HCS ArrayScan showed the number
of viral particles attached to the cell surface was reduced
significantly when the RD cells were pre-treated with the SP40
peptide before addition of virus at 4uC. The results indicated that
Figure 4. The antiviral activities of the SP40 peptide in various cell lines. Vero, HeLa and HT-29 cell lines were pre-treated with the SP40
peptide at various concentrations for 1 hour at room temperature before infection with EV-71 at a MOI of 0.1. (A) The viral induced cytopathic effects
in various cell lines were observed 24-hour post-infection. (B) The viral RNA inhibition that were quantitated by RT TaqMan real-time PCR assay.
doi:10.1371/journal.pone.0034589.g004
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the SP40 peptide probably first interacted with a cell-surface
receptor and subsequently prevented EV-71-cellular receptor
interactions. However, the SP40 peptide lost its antiviral activity
when the peptide was added 1 hour after EV-71 infection.
Previous studies have shown that peptides could play a
significant role in surface protein-protein interactions and could
exert inhibitory activities against viruses like influenza virus [20],
Herpes Simplex virus-1 [21,22], Hepatitis B virus [15], Hepatitis
C virus [14,23], HIV-1 [12], Dengue virus and West Nile virus
Figure 5. Viral attachment assay. (A) RD cells were grown in the chamber slides (Lab-tek, Rochester, USA) and incubated at room temperature for
1 hour with or without the SP40 peptide. This was followed by the incubation of the cells in the cold with EV-71 for 1 hour and washing off the
unbound virions with PBS. RD cell monolayers were fixed with 4% paraformaldehyde and subsequently blocked with Image-iTTM FX Signal Enhancer
(Invitrogen, San Diego, USA). The EV-71 particles were probed with anti-EV-71 monoclonal antibody (Millipore, Billerica, USA) and Alexa Fluor
488 anti-mouse IgG (Invitrogen, San Diego, USA). The nuclei were stained with DAPI for 7uminutes at room temperature. The images were obtained
from the fluorescent microscopy. EV-71 viral particles and cell nuclei were shown in green and blue fluorescence, respectively. The number of virus
particles that was attached to the cell surface were quantitated by (B) Cellomics HCS ArrayScan Spot Detector Bio-Application and (C) RT TaqMan real-
time PCR assay
doi:10.1371/journal.pone.0034589.g005
Figure 6. Alanine scanning analysis. Alanine scanning was performed on the SP40 peptide. Thirteen different peptides were synthesized by
replacing one residue at a time with an A and their inhibitory effect was determined as described above. Activity of each peptide was compared with
the wild-type SP40, which was represented by the red line. Numbers higher than the red line showed a gain of activity whereas a lower number
represented a loss of activity.
doi:10.1371/journal.pone.0034589.g006
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[24]. Although the EV-71 capsid protein VP1 has been reported to
be responsible in mediating viral adsorption and uncoating
process, little information is available about the molecular
interactions of EV-71 and cell receptors [25]. Recently, Chen et
al. [26] had identified several amino acid residues present in the
EV-71 capsid protein VP1 that were critical for the molecular
interaction between EV-71 and the SCARB2 receptor. These
amino acid residues were found within the residues 152–236 of the
VP1 protein. None of the amino acids identified was mapped
within the SP40 peptide amino acid sequence. This finding
suggested that the SP40 peptide probably did not interact with the
SCARB2 receptor.
Figure 7. Proposed locations of the SP40 peptide based on sequence alignment and molecular modeling of poliovirus structure. (A)
The EV-71 strain 41 was aligned with Mahoney poliovirus strain using Clustal W2 program and (B) The molecular structure of poliovirus VP1, VP2, VP3,
and VP4 is represented by purple, blue, brown and green, respectively. The SP40 sequence is indicated in yellow.
doi:10.1371/journal.pone.0034589.g007
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We have demonstrated the importance of the SP40 amino acid
sequence for antiviral activities by comparison with a peptide
carrying scrambled sequence. The inhibitory effect of the
scrambled peptide, SP40X, was significantly lower (at 42.5%)
than the effect observed with the SP40 peptide. Since the amino
acid sequence of the SP40 peptide was highly conserved across all
EV-71 genotypes and was exposed on the surface, this sequence
might carry important motif/domain that interacted with an
unidentified cell-surface receptor. The SP40 peptide could prevent
viral attachment by interacting with cell receptors present on
the surfaces of the RD cells, thereby blocking the availability of the
receptor for attachment of the EV-71 viral particles. The
observation of a significantly reduced IC50 value when RD cells
were pre-treated with SP40 before EV-71 infection strongly
supports this view. The cellular receptor that the SP40 peptide
interacted with remained unknown. However, the SP40 peptide
could also inhibit CV-A16 and poliovirus type 1 infections in vitro,
indicating that the SP40 peptide could interact with a common
receptor that was probably shared by these viruses.
Since the positively charged amino acids were critical for
antiviral activities, the SP40 peptide could interact with cell surface
receptors through electrostatic charge interactions. The antiviral
activity of the SP40 peptide was not restricted to a specific cell
type, but it could block EV-71 infection in different cell lines. This
indicated that the SP40 peptide was probably interacting with the
receptor that was commonly expressed in most cell types.
Interestingly, cell surface glycosaminoglycans are present ubiqui-
tously on the surface of most animal cells and in the extracellular
matrix [27]. The presence of several arginine residues in SP40
draws similarity to the antiviral peptide displaying positively
charged poly-arginine residues against herpes simplex virus-I
(HSV-I) [22]. The antiviral property of the poly-arginine peptide
against HSV-I infection in mice was due to an interaction with
heparan sulfate. Sequence analysis of the SP40 peptide revealed
that it consisted of heparan sulfate glycosaminoglycan specific
binding domains (G1RRRRS6 and R28KVR31) present in bovine
and human lactoferrins [28–30]. Several studies have reported
that lactoferrin was able to bind to ligands such as heparan sulfate
and chondroitin sulfate [28,31,32]. It is possible that through this
interaction lactoferrin was able to inhibit EV-71 infection [33].
These findings suggested that the SP40 peptide could have
interacted with cell surface glycosaminoglycans and prevented EV-
71 attachment.
This is the first time that a small novel viral-based peptide (15-
mer) derived from VP1 is reported to exhibit antiviral activities
against all genotypes and sub-genotypes of EV-71 infection in vitro.
The development and use of antivirals like enviroxime [34],
pleconaril [35], nucleoside analog ribavirin [36] and 3C protease
inhibitors [37] for treating enteroviral infection showed variable
efficacies against the neurotrophic EV-71 virus [38]. Our results
showed that some EV-71 strains were even resistant to ribavirin at
800 mM (unpublished data), this contradicts with the finding of an
IC50 of 266 mM reported by Li et al. [36]. This indicated that
ribavirin might not serve as an effective antiviral agent against all
EV-71 strains. Other antiviral agents like the viral capsid-binding
pyridyl imidazolidinones were found to be ineffective when a
single amino acid mutation occurred at position 192 of the
hydrophobic pocket of the VP1 capsid protein [16]. The SP40
peptide was found to exhibit very similar antiviral properties with
bovine and human lactoferrins which were predicted to prevent
viral attachment, possibly by blocking an unknown cellular
receptor [33,39]. However, the exact antiviral mechanism of
lactoferrin remains to be determined and the SP40 peptide
reported in our study has an even lower IC50 value at 15 mg/ml
when compared to the IC50 value of bovine lactoferrin at 34.5 mg/
ml [33] or human lactoferrin at 103.3–185.0 mg/ml [39,40]. Thus,
SP40 is a good antiviral candidate.
The peptides that blocked the SCARB2 receptor could also be
developed as antiviral agents. Chen et al. [26] have discovered the
amino acid residues in the VP1 capsid protein that are critical for
SCARB2 receptor binding. Interestingly, the amino acids in VP1
that are critical for SCARB2 binding were found in the SP45,
SP55, and SP81 peptides. The amino acid residues that are
important for SCARB2 binding in the SP45, SP55 and SP81
peptides were illustrated in Fig. S1. These peptides were able to
inhibit EV-71 infections in a dose-dependent manner with no
cytotoxicity to the RD cells (unpublished data). Strong synergistic
antiviral activities were observed between the SP40 and the SP81
peptides in RD cells. Since the amino acids critical for binding to
SCARB2 were not present in the SP40 peptide, the data suggested
that the SP40 peptide could have interacted with a different
receptor compared with the SP81 peptide. The additive effects of
these two peptides could have significantly reduced the availability
of receptors for viral attachment.
Inhibition of viruses at the stage of viral attachment provides a
target for therapeutic intervention. Therapeutic peptides have
become an attractive tool in drug discovery due to their active
regulatory role in the biological system and their extreme high
specificity of recognition. The best characterized therapeutic
peptide inhibitor is Enfuvirtide (fusion inhibitor) which mimics the
N terminal sequence in HIV fusion protein, gp41 [12]. Using
peptides as therapeutic agents offer some significant advantages
over small chemical molecules or large therapeutic antibodies. A
major advantage of peptides is their small size and their high
activity and specificity when compared to the antibodies. Peptides
are better candidates to inhibit protein-protein interactions that
comprise a surface area often too large to be inhibited by small
chemical molecules. Peptides accumulate in lesser quantity in
tissues, and have very low cell toxicity when compared to small
synthetic molecules [41]. Antimicrobial peptides such as lactofer-
rin, human b-defensin-2 and dermaseptins have been reported to
exhibit antiviral properties against various viruses [28,42–46].
Therefore, therapeutic peptides have some advantages over the
smaller chemical compounds as antiviral agents.
Since the SP40 peptide works at a very low micromolar
concentration and is non-cytotoxic to RD cells, it is potentially an
excellent candidate for further development as an antiviral agent.
The SP40 peptide was effective when administered before EV-71
infection and could be considered as an excellent candidate for
prophylactic intervention. The exact cellular receptor(s) that the
SP40 peptide interacted with still remained unknown. Further in
vivo studies are needed for development of the SP40 as an antiviral
agent. Although a major disadvantage of peptides is their low
bioavailability due to their rapid degradation in the gastrointes-
tinal system, new formulations, such as the D-isomer peptide and
other delivery options are being developed to circumvent these
disadvantages [41].
Supporting Information
Figure S1 Diagrammatic illustration of EV-71 VP1
secondary structure. Cylinder and arrow represent a-helix
structure and b-sheet, respectively. The effects of mutations
examined as to which amino acids were interacting with the
SCARB2 receptor was marked as follows: Filled circle indicates
those most effective residues for viral binding and infection; open
circle indicates partial effective residues [26]. The amino acid
sequences of SP40, SP45, SP55 and SP81-83 were shown to
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correspond to their secondary structure and location within the
VP1 capsid protein.
(TIF)
Table S1 VP1 protein sequences among enteroviruses.
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